The primary outcome of the trial is to determine dose-limiting toxicities during the first two cycles of therapy while secondary outcomes involve the identification of treatment-emergent adverse events (TEAEs) and objective tumor response
A Swedish registry (n = 12,277, 19802006) showed that RYGB was associated with a two-fold greater risk of inpatient AUD treatment than LAGB [281] and the controlled Swedish Obese Subjects study confirmed an elevated risk after gastric bypass [282]
Monitor for excessive gastrointestinal distress (nausea, vomiting, diarrhoea), significant mood changes or anxiety, unusual fatigue, sleep disturbances, and signs of dehydration
For most patients, the medication does the heavy clinical lifting
In the intestines, activation of FXR also regulates glucose and lipid metabolism [61] [62]